


PROTAC PLK1 Degradator-1

Cat. No.:	HY-157427
Molecular Formula:	C ₁₁₃ H ₂₁₀ N ₅₇ O ₂₂ P
Molecular Weight:	2750.27
Target:	PROTACs; Polo-like Kinase (PLK)
Pathway:	PROTAC; Cell Cycle/DNA Damage
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	PROTAC PLK1 Degradator-1 (DD-2) is a potent PROTAC PLK1 degrader. PROTAC PLK1 Degradator-1 selectively induces PLK1 degradation in cancer cells, including HeLa (DC ₅₀ =2.5 μM) and nonsmall cell lung cancer (NSCLC), through the N-degron pathway ^[1] .
IC₅₀ & Target	PLK1
In Vitro	PROTAC PLK1 Degradator-1 (DD-2) (0-50 μM, 24 h) exhibits significant in vitro anticancer effects, inducing G2/M arrest and apoptosis in HeLa and NSCLC cell lines ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	PROTAC PLK1 Degradator-1 (DD-2) (10 mg/kg, tail vein) shows significant tumor growth inhibition in a xenograft mouse model using HeLa and NSCLC cell lines ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Gunasekaran P, et al. Degradation of Polo-like Kinase 1 by the Novel Poly-Arginine N-Degron Pathway PROTAC Regulates Tumor Growth in Nonsmall Cell Lung Cancer. J Med Chem. 2023 Dec 17.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA